Bringing the fundamentals into focus…
Back to Viridian Therapeutics, Inc.
How Viridian Therapeutics, Inc. stacks up
VRDN · against 315 other Healthcare companies of similar size
Growth
99/ 100
Near the top of its peers.
Ranked #2 of 316 · scores higher than 98% of peers
Bars: peers in each 10-point band of the growth score43 peers with a growth score of 90–100, including VRDN · Click a bar to see the companies
Why growth scores 99?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its revenue growth and 3-year revenue growth, which are stronger than most Healthcare peers.
- Earnings per share growth is not reported, so it is left out of the score.
- faster revenue growth over three years: stronger than 99% of peers. 3-year revenue growth: 264.4% vs peer median 5.8%
- faster revenue growth over the last year: stronger than 100% of peers. Revenue growth: 23220.3% vs peer median 6.1%
Metric by metric
Position: dot = VRDN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | VRDN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 315 reported | 23220.3% | 7.1% | 100% | 33% | |
| Earnings per share growthHigher is better · 186 reported | Not reported | 10.9% | — | — | 33% |
| 3-year revenue growthHigher is better · 308 reported | 264.4% | 8.0% | 99% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around VRDN| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 27.6B SEK (≈$2.8B) | 99 | 76 | |
| 2 | 2.1B USD | 99 | 96 | |
| 2 | 2.8B USD | 99 | 51 | |
| 2 | 15.6B DKK (≈$2.3B) | 99 | 96 | |
| 7 | 19.7B HKD (≈$2.5B) | 98 | 84 | |
| 7 | 37.3B HKD (≈$4.8B) | 98 | 90 | |
| 7 | 3.8B USD | 98 | 71 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score